menu
    • menu
    [{"orgOrder":0,"company":"PentixaPharm","sponsor":"Elsa Eckert Life Science Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide","year":"2020","type":"Series A Financing","leadProduct":"Pentixafor","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Elsa Eckert Life Science Accelerator","highestDevelopmentStatusID":"6","companyTruncated":"PentixaPharm \/ Elsa Eckert Life Science Accelerator"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"BankM AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Y90-PentixaTher","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ BankM AG","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ BankM AG"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu PentixaTher","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by PentixaPharm

    Menu

    PentixaPharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PentixaPharm

                            Germany arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu PentixaTher

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lu177-PentixaTher Trial Begins for AML and ALL, Supporting Radiotherapy Evidence

                            Details : Lu177-PentixaTher is a novel radiopharmaceutical therapy, being investigated in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

                            Product Name : [90Y]Y-PTT

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 21, 2024

                            Lead Product(s) : 177-Lu PentixaTher

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PentixaPharm

                            Germany arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Y90-PentixaTher

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BankM AG

                            Deal Size : $22.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Pentixapharm Scores $22M in IPO to Advance Radiopharma Trials

                            Details : The proceeds will focus on the clinical development and approval of company's lead candidates Ga68-PentixaFor and Y90-PentixaTher.

                            Product Name : Y90-PentixaTher

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 10, 2024

                            Lead Product(s) : Y90-PentixaTher

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BankM AG

                            Deal Size : $22.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PentixaPharm

                            Germany arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentixafor

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Elsa Eckert Life Science Accelerator

                            Deal Size : $16.2 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            PENTIXAPHARM Secures € 15 Million Series A Financing

                            Details : Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            June 02, 2020

                            Lead Product(s) : Pentixafor

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Elsa Eckert Life Science Accelerator

                            Deal Size : $16.2 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth